Opexa Therapeutics (OPXA) 0.77 $OPXA
Small Cap Profiles: OPXA, NEWC, TRNS, MLER
ACCESSWIRE - Thu Dec 11, 9:35AM CST
WHITEFISH, MT / ACCESSWIRE / December 11, 2014 /
TRNS: 10.05 (-0.05), BIIB: 344.49 (+2.16), OPXA: 0.77 (+0.01), SNY: 45.16 (-1.05)
Opexa Therapeutics Selected as One of the "Top 10 Advanced Therapy Projects to Watch"
Business Wire - Tue Nov 18, 8:02AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced Opexa has been named one of the "Top 10 Advanced Therapy Projects to Watch" by Elsevier Business Intelligence for the second consecutive year. As part of this recognition, Neil K. Warma, Opexa's President and Chief Executive Officer, will present a company overview at the Therapeutic Area Partnerships meeting taking place on November 19-21, 2014, at the Hyatt Regency Boston. Mr. Warma will present on Thursday, November 20 at 2:25 p.m. E.S.T.
OPXA: 0.77 (+0.01)
Pieris Appoints Michael Richman as Supervisory Board Member
Marketwired - Wed Nov 12, 9:15AM CST
Pieris AG announced today the appointment of Michael Richman as a member of its Supervisory Board.
OPXA: 0.77 (+0.01)
Opexa Therapeutics CEO Invited to Join Personalized Medicine Panel at New York CEO Conference
Business Wire - Tue Nov 11, 8:00AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that Neil K. Warma, Opexa's President and Chief Executive Officer, has been invited as a panel member to participate in the New York CEO Conference. The event will take place November 12 - 13, 2014, at the Apella in New York.
OPXA: 0.77 (+0.01)
Update: Opexa Q3 Earnings, Buyout Thesis Remains Intact
Trevor Lowenthal - at Seeking Alpha - Fri Nov 07, 4:52AM CST
OPXA: 0.77 (+0.01), MRK: 57.72 (-1.62)
Opexa Therapeutics Reports Third Quarter 2014 Financial Results and Provides Corporate Update
Business Wire - Thu Nov 06, 3:02PM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and Neuromyelitis Optica (NMO), today reported financial results for the third quarter ended September 30, 2014 and provided an overview of the Company's recent corporate developments.
OPXA: 0.77 (+0.01)
Opexa reports November 6
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 8:50AM CST
OPXA: 0.77 (+0.01)
Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Third Quarter 2014 Financial Results
Business Wire - Wed Nov 05, 8:00AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that the Company will report financial results for the three months ended September 30, 2014 after the close of trading on Thursday, November 6th. The Company will also conduct a conference call and webcast to discuss financial results and provide a corporate update at 5:00 P.M. EST on Thursday, November 6th.
OPXA: 0.77 (+0.01)
Opexa Therapeutics Supports National Multiple Sclerosis Society and Walk MS
Business Wire - Wed Oct 22, 8:02AM CDT
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced its partnership with the National Multiple Sclerosis Society, Lone Star Chapter, as a sponsor of the nonprofit's annual Houston area Walk MS fundraisers for the fourth consecutive year.
OPXA: 0.77 (+0.01)
Opexa Therapeutics to Present at Cleveland Clinic's 12th Annual Medical Innovation Summit
Business Wire - Mon Oct 20, 8:03AM CDT
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and Neuromyelitis Optica (NMO), today announced that Neil K. Warma, the Company's President and Chief Executive Officer, has been invited to present at the Cleveland Clinic's 12th Annual Medical Innovation Summit, taking place October 26-29, 2014, in Cleveland, Ohio.
OPXA: 0.77 (+0.01)
Opexa Therapeutics Announces Analyst and Investor Event
Business Wire - Thu Oct 02, 1:09PM CDT
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and Neuromyelitis Optica (NMO), today announced that it will hold an Analyst and Investor Event in New York City, New York on Thursday, October 9, 2014.
OPXA: 0.77 (+0.01)
Opexa Strengthens Patent Portfolio with Expansion Into B-cell Diseases and Announces Allowance of 98th T-cell Patent
Business Wire - Mon Sep 29, 8:02AM CDT
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and Neuromyelitis Optica (NMO), today announced the expansion of its intellectual property portfolio. Opexa's intellectual property portfolio has grown to reach 98 issued and validated patents worldwide. Additionally, Opexa is expanding its IP protection to cover B-cell mediated diseases in connection with its recently announced development program in Neuromyelitis Optica.
OPXA: 0.77 (+0.01)
Investors look to Lighten Up on Shares of Opexa Therapeutics, Shares Down 7.6% (OPXA)
Comtex SmarTrend(R) - Thu Sep 25, 11:37AM CDT
Opexa Therapeutics (NASDAQ:OPXA) is one of today's worst performing penny stocks, down 7.6% to $0.85 on 1.3x average daily volume. Thus far today, Opexa Therapeutics has traded 316,000 shares, vs. average volume of 241,000 shares per day. The stock has underperformed the Dow (-7.6% to the Dow's -1.5%) and underperformed the S&P 500 (-7.6% to the S&P's -1.5%) during today's trading.
OPXA: 0.77 (+0.01)
Opexa Therapeutics Up 5.6%, Shares Break Through Resistance (OPXA)
Comtex SmarTrend(R) - Thu Sep 18, 10:37AM CDT
Opexa Therapeutics (NASDAQ:OPXA) is one of today's best performing low-priced stocks, up 5.6% to $1.14 on 1.1x average daily volume. Opexa Therapeutics has traded 211,000 shares thus far today, vs. average volume of 200,000 shares per day. The stock has outperformed the Dow (5.6% to the Dow's 0.5%) and outperformed the S&P 500 (5.6% to the S&P's 0.4%) during today's trading.
OPXA: 0.77 (+0.01)
Opexa Therapeutics, Inc. Announces Termination of Public Offering of Common Stock
Business Wire - Tue Sep 16, 7:30AM CDT
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), today announced that it has terminated the public offering of shares of its common stock previously announced on Monday, September 15, 2014. The termination results from an assessment by Opexa's management that current market conditions are not conducive for an offering on terms that would be in the best interests of Opexa's stockholders. As a result of such termination, no shares will be sold pursuant to the offering.
OPXA: 0.77 (+0.01)
Global and Chinese Stem Cell Industry Report, 2014-2017
M2 - Tue Sep 16, 6:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hhmz42/global_and) has announced the addition of the "Global and Chinese Stem Cell Industry Report, 2014-2017" report to their offering. Currently, cord blood bank is the fastest-growing and relatively mature market amid stem cell upstream sectors and even the whole industry chain. In 2005, there were 23 cord blood banks worldwide and in 2013 the figure exceeded 480. Global cord blood stem cell (CBSC) storage companies can be roughly divided into two categories: the ones running in a globalized business model, such as Cryo-Cell International and Esperite (formerly known as Cryo-Save Group), and the others giving priority to regional operation e.g. Zhongyuan Union Stem Cell Bioengineering (VCANBIO), Golden Meditech and LifeCell International. However, the companies mainly engaged in cord blood bank business are currently small in scale, only a few with more than 500,000 clients. The stem cell technology and product research-oriented midstream sector is in its infancy, mostly concentrated in few countries like Europe, America and South Korea. At present, most companies in the industry chain are basically in the red for years running due to huge R&D costs. Nevertheless, attracted by the tremendous market potential in the area of stem cell therapy and enjoying the great encouragement from government policies (e.g. capital subsidy) and the capital support of significant cooperative partners, very few companies have dropped out. Up to now, altogether 9 sorts of stem cell products have been approved worldwide, 3 of which are in the category of stem cell drugs developed by S. Korean companies, such as MEDIPOST's adult stem cell drug CARTISTEM for osteoarthritis treatment and the stem cell product Prochymal (MEDIPOST obtained the product via acquiring the Therapeutics business of Osiris Therapeutics) direct at treating children suffering acute graft-versus-host disease (GVHD). In the meantime, traditional pharmaceutical giants like Novartis are setting about quickly accessing the field through mergers and acquisitions. On Aug. 19, 2014, Novartis reached an acquisition agreement with Gamida Cell (a corporate dedicated to stem cell technology R&D and its application in stem cell transplantation for leukemia patients), which specified that Novartis spend USD35 million in acquiring 15% equity in the latter and win the option to take over the remaining equity in two years with USD165 million; in Sep. 2013, Novartis also entered a cooperation with Regenerex to jointly develop the hematopoietic stem cell platform FCRx of the latter. Key Topics Covered: 1. Overview of Stem Cell Industry 2. Global Stem Cell Industry Chain 3. China Stem Cell Industry Chain 4. Upstream Enterprises 5. Midstream and Downstream Enterprises Companies Mentioned - Advanced Cell Technology - Athersys - Beike Biotechnology - Celgene - Cryo-Cell International - Cryosite - Cyagen Biosciences - Cytori Therapeutics - Esperite - Golden Meditech - LifeCell International - MEDIPOST - Mesoblast - NeoStem - Opexa Therapeutics - Orthofix International - Osiris Therapeutics - Pluristem Therapeutics - Reneuron - StemCells - Tigenix - Vitro Biopharma - ZhongKe Biopharm - Zhongyuan Union Stem Cell Bioengineering For more information visit http://www.researchandmarkets.com/research/hhmz42/global_and
OPXA: 0.77 (+0.01), PSTI: 2.60 (+0.01), CYTX: 0.53 (+0.05), OSIR: 12.92 (-0.04), NVS: 93.52 (-0.82), CELGZ: 3.51 (-0.03)
Market Maker Surveillance Report. NPSP, RADA, MGPI, OPXA, RLOC, NETE, Losing Stocks With Lowest Price Friction For Monday, September 15th 2014
M2 - Tue Sep 16, 5:59AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 4654 companies with "abnormal" market making, 1512 companies with positive Friction Factors and 3686 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Monday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. NPS Pharmaceuticals Inc (NASDAQ:NPSP), Rada Electronic Industries Ltd (NASDAQ:RADA), MGP Ingredients Inc (NASDAQ:MGPI), Opexa Therapeutics Inc (NASDAQ:OPXA), REACHLOCAL INCORPORATION (NASDAQ:RLOC), NET ELEMENT INC (OTC:NETE). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
NETE: 1.16 (-0.12), OPXA: 0.77 (+0.01), RADA: 2.60 (+0.10), NPSP: 31.28 (-0.99), RLOC: 3.19 (+0.02), MGPI: 15.78 (-0.62)
Opexa Therapeutics to issue public offering of common shares
M2 - Tue Sep 16, 5:57AM CDT
Biopharmaceutical company company Opexa Therapeutics (NasdaqCM:OPXA) said on Monday that it plans to offer shares of its common stock in a public offering.
OPXA: 0.77 (+0.01)
Opexa Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
Business Wire - Mon Sep 15, 3:21PM CDT
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), today announced that it intends to offer shares of its common stock in an underwritten public offering. All of the shares in the offering are to be sold by Opexa. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
OPXA: 0.77 (+0.01)
Momenta Gains on Purchase of Autoimmune Antibodies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 11, 4:45PM CDT
Momenta Pharmaceuticals, Inc. (MNTA) will use the antibodies acquired from AnaptysBio for developing a novel recombinant antibody targeting specific autoimmune disorders.
OPXA: 0.77 (+0.01), GILD: 104.13 (-0.18), BAX: 71.77 (-1.34), MNTA: 12.16 (-0.04)
Small Cap Profiles: OPXA, NEWC, TRNS, MLER
ACCESSWIRE - Thu Dec 11, 9:35AM CST
WHITEFISH, MT / ACCESSWIRE / December 11, 2014 /
TRNS: 10.05 (-0.05), BIIB: 344.49 (+2.16), OPXA: 0.77 (+0.01), SNY: 45.16 (-1.05)
Opexa Therapeutics Selected as One of the "Top 10 Advanced Therapy Projects to Watch"
Business Wire - Tue Nov 18, 8:02AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced Opexa has been named one of the "Top 10 Advanced Therapy Projects to Watch" by Elsevier Business Intelligence for the second consecutive year. As part of this recognition, Neil K. Warma, Opexa's President and Chief Executive Officer, will present a company overview at the Therapeutic Area Partnerships meeting taking place on November 19-21, 2014, at the Hyatt Regency Boston. Mr. Warma will present on Thursday, November 20 at 2:25 p.m. E.S.T.
OPXA: 0.77 (+0.01)
Pieris Appoints Michael Richman as Supervisory Board Member
Marketwired - Wed Nov 12, 9:15AM CST
Pieris AG announced today the appointment of Michael Richman as a member of its Supervisory Board.
OPXA: 0.77 (+0.01)
Opexa Therapeutics CEO Invited to Join Personalized Medicine Panel at New York CEO Conference
Business Wire - Tue Nov 11, 8:00AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that Neil K. Warma, Opexa's President and Chief Executive Officer, has been invited as a panel member to participate in the New York CEO Conference. The event will take place November 12 - 13, 2014, at the Apella in New York.
OPXA: 0.77 (+0.01)
Update: Opexa Q3 Earnings, Buyout Thesis Remains Intact
Trevor Lowenthal - at Seeking Alpha - Fri Nov 07, 4:52AM CST
OPXA: 0.77 (+0.01), MRK: 57.72 (-1.62)
Opexa Therapeutics Reports Third Quarter 2014 Financial Results and Provides Corporate Update
Business Wire - Thu Nov 06, 3:02PM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and Neuromyelitis Optica (NMO), today reported financial results for the third quarter ended September 30, 2014 and provided an overview of the Company's recent corporate developments.
OPXA: 0.77 (+0.01)
Opexa reports November 6
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 8:50AM CST
OPXA: 0.77 (+0.01)
Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Third Quarter 2014 Financial Results
Business Wire - Wed Nov 05, 8:00AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that the Company will report financial results for the three months ended September 30, 2014 after the close of trading on Thursday, November 6th. The Company will also conduct a conference call and webcast to discuss financial results and provide a corporate update at 5:00 P.M. EST on Thursday, November 6th.
OPXA: 0.77 (+0.01)
Opexa Therapeutics Supports National Multiple Sclerosis Society and Walk MS
Business Wire - Wed Oct 22, 8:02AM CDT
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced its partnership with the National Multiple Sclerosis Society, Lone Star Chapter, as a sponsor of the nonprofit's annual Houston area Walk MS fundraisers for the fourth consecutive year.
OPXA: 0.77 (+0.01)
Opexa Therapeutics to Present at Cleveland Clinic's 12th Annual Medical Innovation Summit
Business Wire - Mon Oct 20, 8:03AM CDT
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and Neuromyelitis Optica (NMO), today announced that Neil K. Warma, the Company's President and Chief Executive Officer, has been invited to present at the Cleveland Clinic's 12th Annual Medical Innovation Summit, taking place October 26-29, 2014, in Cleveland, Ohio.
OPXA: 0.77 (+0.01)
Opexa Therapeutics Announces Analyst and Investor Event
Business Wire - Thu Oct 02, 1:09PM CDT
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and Neuromyelitis Optica (NMO), today announced that it will hold an Analyst and Investor Event in New York City, New York on Thursday, October 9, 2014.
OPXA: 0.77 (+0.01)
Opexa Strengthens Patent Portfolio with Expansion Into B-cell Diseases and Announces Allowance of 98th T-cell Patent
Business Wire - Mon Sep 29, 8:02AM CDT
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and Neuromyelitis Optica (NMO), today announced the expansion of its intellectual property portfolio. Opexa's intellectual property portfolio has grown to reach 98 issued and validated patents worldwide. Additionally, Opexa is expanding its IP protection to cover B-cell mediated diseases in connection with its recently announced development program in Neuromyelitis Optica.
OPXA: 0.77 (+0.01)
Investors look to Lighten Up on Shares of Opexa Therapeutics, Shares Down 7.6% (OPXA)
Comtex SmarTrend(R) - Thu Sep 25, 11:37AM CDT
Opexa Therapeutics (NASDAQ:OPXA) is one of today's worst performing penny stocks, down 7.6% to $0.85 on 1.3x average daily volume. Thus far today, Opexa Therapeutics has traded 316,000 shares, vs. average volume of 241,000 shares per day. The stock has underperformed the Dow (-7.6% to the Dow's -1.5%) and underperformed the S&P 500 (-7.6% to the S&P's -1.5%) during today's trading.
OPXA: 0.77 (+0.01)
Opexa Therapeutics Up 5.6%, Shares Break Through Resistance (OPXA)
Comtex SmarTrend(R) - Thu Sep 18, 10:37AM CDT
Opexa Therapeutics (NASDAQ:OPXA) is one of today's best performing low-priced stocks, up 5.6% to $1.14 on 1.1x average daily volume. Opexa Therapeutics has traded 211,000 shares thus far today, vs. average volume of 200,000 shares per day. The stock has outperformed the Dow (5.6% to the Dow's 0.5%) and outperformed the S&P 500 (5.6% to the S&P's 0.4%) during today's trading.
OPXA: 0.77 (+0.01)
Opexa Therapeutics, Inc. Announces Termination of Public Offering of Common Stock
Business Wire - Tue Sep 16, 7:30AM CDT
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), today announced that it has terminated the public offering of shares of its common stock previously announced on Monday, September 15, 2014. The termination results from an assessment by Opexa's management that current market conditions are not conducive for an offering on terms that would be in the best interests of Opexa's stockholders. As a result of such termination, no shares will be sold pursuant to the offering.
OPXA: 0.77 (+0.01)
Global and Chinese Stem Cell Industry Report, 2014-2017
M2 - Tue Sep 16, 6:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hhmz42/global_and) has announced the addition of the "Global and Chinese Stem Cell Industry Report, 2014-2017" report to their offering. Currently, cord blood bank is the fastest-growing and relatively mature market amid stem cell upstream sectors and even the whole industry chain. In 2005, there were 23 cord blood banks worldwide and in 2013 the figure exceeded 480. Global cord blood stem cell (CBSC) storage companies can be roughly divided into two categories: the ones running in a globalized business model, such as Cryo-Cell International and Esperite (formerly known as Cryo-Save Group), and the others giving priority to regional operation e.g. Zhongyuan Union Stem Cell Bioengineering (VCANBIO), Golden Meditech and LifeCell International. However, the companies mainly engaged in cord blood bank business are currently small in scale, only a few with more than 500,000 clients. The stem cell technology and product research-oriented midstream sector is in its infancy, mostly concentrated in few countries like Europe, America and South Korea. At present, most companies in the industry chain are basically in the red for years running due to huge R&D costs. Nevertheless, attracted by the tremendous market potential in the area of stem cell therapy and enjoying the great encouragement from government policies (e.g. capital subsidy) and the capital support of significant cooperative partners, very few companies have dropped out. Up to now, altogether 9 sorts of stem cell products have been approved worldwide, 3 of which are in the category of stem cell drugs developed by S. Korean companies, such as MEDIPOST's adult stem cell drug CARTISTEM for osteoarthritis treatment and the stem cell product Prochymal (MEDIPOST obtained the product via acquiring the Therapeutics business of Osiris Therapeutics) direct at treating children suffering acute graft-versus-host disease (GVHD). In the meantime, traditional pharmaceutical giants like Novartis are setting about quickly accessing the field through mergers and acquisitions. On Aug. 19, 2014, Novartis reached an acquisition agreement with Gamida Cell (a corporate dedicated to stem cell technology R&D and its application in stem cell transplantation for leukemia patients), which specified that Novartis spend USD35 million in acquiring 15% equity in the latter and win the option to take over the remaining equity in two years with USD165 million; in Sep. 2013, Novartis also entered a cooperation with Regenerex to jointly develop the hematopoietic stem cell platform FCRx of the latter. Key Topics Covered: 1. Overview of Stem Cell Industry 2. Global Stem Cell Industry Chain 3. China Stem Cell Industry Chain 4. Upstream Enterprises 5. Midstream and Downstream Enterprises Companies Mentioned - Advanced Cell Technology - Athersys - Beike Biotechnology - Celgene - Cryo-Cell International - Cryosite - Cyagen Biosciences - Cytori Therapeutics - Esperite - Golden Meditech - LifeCell International - MEDIPOST - Mesoblast - NeoStem - Opexa Therapeutics - Orthofix International - Osiris Therapeutics - Pluristem Therapeutics - Reneuron - StemCells - Tigenix - Vitro Biopharma - ZhongKe Biopharm - Zhongyuan Union Stem Cell Bioengineering For more information visit http://www.researchandmarkets.com/research/hhmz42/global_and
OPXA: 0.77 (+0.01), PSTI: 2.60 (+0.01), CYTX: 0.53 (+0.05), OSIR: 12.92 (-0.04), NVS: 93.52 (-0.82), CELGZ: 3.51 (-0.03)
Market Maker Surveillance Report. NPSP, RADA, MGPI, OPXA, RLOC, NETE, Losing Stocks With Lowest Price Friction For Monday, September 15th 2014
M2 - Tue Sep 16, 5:59AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 4654 companies with "abnormal" market making, 1512 companies with positive Friction Factors and 3686 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Monday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. NPS Pharmaceuticals Inc (NASDAQ:NPSP), Rada Electronic Industries Ltd (NASDAQ:RADA), MGP Ingredients Inc (NASDAQ:MGPI), Opexa Therapeutics Inc (NASDAQ:OPXA), REACHLOCAL INCORPORATION (NASDAQ:RLOC), NET ELEMENT INC (OTC:NETE). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
NETE: 1.16 (-0.12), OPXA: 0.77 (+0.01), RADA: 2.60 (+0.10), NPSP: 31.28 (-0.99), RLOC: 3.19 (+0.02), MGPI: 15.78 (-0.62)
Opexa Therapeutics to issue public offering of common shares
M2 - Tue Sep 16, 5:57AM CDT
Biopharmaceutical company company Opexa Therapeutics (NasdaqCM:OPXA) said on Monday that it plans to offer shares of its common stock in a public offering.
OPXA: 0.77 (+0.01)
Opexa Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
Business Wire - Mon Sep 15, 3:21PM CDT
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), today announced that it intends to offer shares of its common stock in an underwritten public offering. All of the shares in the offering are to be sold by Opexa. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
OPXA: 0.77 (+0.01)
Momenta Gains on Purchase of Autoimmune Antibodies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 11, 4:45PM CDT
Momenta Pharmaceuticals, Inc. (MNTA) will use the antibodies acquired from AnaptysBio for developing a novel recombinant antibody targeting specific autoimmune disorders.
OPXA: 0.77 (+0.01), GILD: 104.13 (-0.18), BAX: 71.77 (-1.34), MNTA: 12.16 (-0.04)
